Skip to main content

Table 1 Baseline characteristics of the patients according to the study groups

From: Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia

Variable

Total (n = 116)

Vancomycin (n = 54)

Teicoplanin (n = 62)

p value

Male

92 (79.3%)

39 (72.2%)

53 (85.5%)

0.079

Age (years)

61.4 ± 13.1

67.7 ± 12.9

67.2 ± 13.4

0.842

Body mass index (kg/m2)

21.3 ± 4.3

20.5 ± 4.6

22.1 ± 3.9

0.050

Coexisting condition

 DM

33 (28.4%)

14 (25.9%)

19 (30.6%)

0.574

 HTN

46 (39.7%)

19 (35.2%)

27 (43.5%)

0.358

 Pulmonary disease

38 (32.8%)

11 (20.4%)

27 (43.5%)

0.009

 Cardiovascular disease

31 (26.7%)

10 (18.5%)

21 (33.9%)

0.062

 Renal disease

12 (10.3%)

6 (11.1%)

6 (9.7%)

0.800

 Cerebrovascular disease

31 (26.7%)

21 (38.9%)

10 (16.1%)

0.006

 Liver diseasea

10 (8.6%)

3 (5.6%)

7 (11.3%)

0.334

 History of transplantationa

10 (8.6%)

9 (16.7%)

1 (1.6%)

0.006

 Malignancy

0.288

  Solid

33 (28.4%)

14 (25.9%)

19 (30.6%)

 

  Hematologic

10 (8.6%)

7 (13.0%)

3 (4.8%)

 

 Recent chemotherapy

26 (22.4%)

11 (20.4%)

15 (24.2%)

0.622

 Recent radiotherapya

6 (5.2%)

3 (5.6%)

3 (4.8%)

> 0.999

 Neurologic disease

19 (16.4%)

10 (18.5%)

9 (14.5%)

0.561

Type of pneumonia

0.107

 CAP

37(31.9%)

17 (31.5%)

20 (32.3%)

 

 HAP

37 (31.9%)

22 (40.7%)

15 (24.2%)

 

 VAP

42 (36.2%)

15 (27.8%)

27 (43.5%)

 

Bacteremia

20 (17.2%)

10 (18.5%)

10 (16.1%)

0.734

MIC

    

 Vancomycin

   

0.569

  ≤ 0.5

1 (0.9%)

0 (0.0%)

1 (1.6%)

 

  1

87 (75.0%)

42 (77.8%)

45 (72.6%)

 

  2

28 (24.1%)

12 (22.2%)

16 (25.8%)

 

 Teicoplanina

   

> 0.999

  ≤ 4

112 (96.6%)

52 (96.3%)

60 (96.8%)

 

  8

4 (3.4%)

2 (3.7%)

2 (3.2%)

 

Initial vital sign

 

 SBP

121.5 ± 22.6

119.8 ± 21.3

123.0 ± 23.7

0.448

 DBP

68.0 ± 13.9

67.1 ± 14.5

68.7 ± 13.4

0.517

 Pulse rate

98.9 ± 21.4

99.8 ± 21.6

98.2 ± 21.5

0.699

 Body temperature

37.2 ± 0.8

37.2 ± 0.8

37.2 ± 0.8

0.673

 Respiratory rateb

22.3 ± 5.8

21.9 ± 6.0

22.7 ± 5.7

0.801

Mechanical ventilation

70 (60.3%)

30 (55.6%)

40 (64.5%)

0.325

Systemic steroids

31 (26.7%)

13 (24.1%)

18 (29.0%)

0.547

APACHE II scoreb

13.5 ± 5.3

13.1 ± 5.4

13.9 ± 5.2

0.324

White blood cell counts

11.9 ± 5.7

11.6 ± 5.6

12.1 ± 5.9

0.609

C-reactive proteinb

11.0 ± 8.6

12.1 ± 7.9

10.1 ± 9.2

0.045

Procalcitonin (n = 79) b

5.4 ± 19.1

1.5 ± 2.8

9.4 ± 26.6

0.367

Creatinineb

1.2 ± 1.2

1.1 ± 1.2

1.3 ± 1.1

0.008

Vancomycin serum trough levels (µg/mL)

 Day 3 (n = 45)

n/a

13.5 ± 8.1

n/a

 

 Day 6 (n = 34)

n/a

20.4 ± 8.3

n/a

 

 Day 9 (n = 29)

n/a

17.3 ± 4.7

n/a

 

Teicoplanin regimen

 

 High-dose regimen

n/a

n/a

15 (24.2%)

 

 Low-dose regimen

n/a

n/a

47 (75.8%)

 

Therapeutic duration, daysb

14.7 ± 8.2

14.7 ± 9.1

14.7 ± 7.4

0.658

  1. APACHE II score Acute Physiology and Chronic Health Enquiry II score, CAP community-acquired pneumonia, DBP diastolic blood pressure, DM diabetes mellitus, HAP hospital-acquired pneumonia, HTN hypertension, MIC minimal inhibition concentration, SBP systolic blood pressure, VAP ventilator-associated pneumonia
  2. aVariables analyzed using Fisher’s exact test
  3. bVariables analyzed using the Mann–Whitney U test